Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 Sep 1.

Published in final edited form as: J Allergy Clin Immunol Pract. 2020 Apr 26;8(8):2761–2768.e16. doi: 10.1016/j.jaip.2020.04.030

Follow-up in a case of SSM with a history of recurrent episodes of life-threatening anaphylactic reactions. (A) Serum tryptase levels () and IgE () in patient number 26 (SSM) suffering from recurrent life-threatening anaphylaxis (). Following 2 series of 2CdA-cycles (), a temporary control of symptoms was achieved. After recurrence of severe anaphylactic episodes, omalizumab-therapy () was initiated, followed by marked improvement. (B) Allergen-chip was performed 6 years after diagnosis, before 2CdA, 12 years after diagnosis, and 26 years after diagnosis. 2CdA, 2-Chlorodeoxyadenosine (=cladribine).

Inline graphic — Follow-up in a case of SSM with a history of recurrent episodes of life-threatening anaphylactic reactions. (A) Serum tryptase levels () and IgE () in patient number 26 (SSM) suffering from recurrent life-threatening anaphylaxis (). Following 2 series of 2CdA-cycles (), a temporary control of symptoms was achieved. After recurrence of severe anaphylactic episodes, omalizumab-therapy () was initiated, followed by marked improvement. (B) Allergen-chip was performed 6 years after diagnosis, before 2CdA, 12 years after diagnosis, and 26 years after diagnosis. 2CdA, 2-Chlorodeoxyadenosine (=cladribine).